Chercheur

    Georges-Etienne Rivard , M.D.

    george-etienne.rivard@umontreal.ca
    Georges-Etienne Rivard
    Axe de recherche
    Maladies virales, immunitaires et cancers
    Thème de recherche
    Maladies hématologiques sévères
    Adresse
    CHUSJ - Centre de Recherche

    Téléphone
    514 345-4931 #6717

    Fax
    514 345-4884

    Sommaire de carrière

    Depuis des années, les intérêts de recherche de Georges-Étienne Rivard portent sur la pharmacologie, l'hémophilie et les hémorragies. Plus précisément, ses recherches sont axées sur la chronopharmacologie du traitement de la leucémie infantile.

    Il a démontré que les antimétabolites, notamment la 6-mercaptopurine, semble s'avérer plus efficace dans le traitement de la leucémie aiguë lymphoblastique lorsqu'elle est administrée le soir plutôt que le matin. Il a également révélé que la 6-mercaptopurine ne doit pas être administrée en association avec le lait qui contient de la xanthine oxydase et qui peut cataboliser jusqu'à 40 % de la 6-mercaptopurine, la rendant inefficace.

    Grâce à ses nombreuses publications sur l'utilisation du phosphate de chrome colloïdal P32 dans le traitement de l'arthropathie hémophilique chronique, cette technique s'est largement répandue en Amérique du Nord. L'identification d'une rare hémorragie congénitale, dénommée initialement le facteur V Québec, a mené à une collaboration avec plusieurs chercheurs nord-américains dont les résultats sont parus dans de bon nombre de publications au fil des ans. En collaboration avec un groupe de chercheurs de l'Université McMaster, Georges-Étienne Rivard contribue encore activement à la recherche sur cette hémorragie maintenant connue sous le nom du syndrome plaquettaire du Québec.

Publications

Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH - Chitlur M, Rivard G-É, Lillicrap D, Mann K, Shima M, Young G, Factor VIII, Factor IX, and Rare Coagulation Disorders Subcommittee of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12(1): 103-106.

Stereological analysis of subchondral angiogenesis induced by chitosan and coagulation factors in microdrilled articular cartilage defects - Mathieu C, Chevrier A, Lascau-Coman V, Rivard G-É, Hoemann CD. Stereological analysis of subchondral angiogenesis induced by chitosan and coagulation factors in microdrilled articular cartilage defects. Osteoarthr Cartilage 2013; 21(6): 849-859.

Product-dependent anti-factor VIII antibodies - Butenas S, Krudysz-Amblo J, Rivard G-É, Mann K. Product-dependent anti-factor VIII antibodies. Haemophilia 2013; 19(4): 619-625.

An 'ice age' concept? The use of ice in the treatment of acute haemarthrosis in haemophilia - Forsyth AL, Zourikian N, Rivard G-É, Valentino LA. An 'ice age' concept? The use of ice in the treatment of acute haemarthrosis in haemophilia. Haemophilia 2013; 19(6): e393-396.

From principle to practice: bridging the gap in patient profiling - Foley JH, Orfeo T, Undas A, McLean KC, Bernstein IM, Rivard G-É, Mann K, Everse SJ, Brummel Ziedins K. From principle to practice: bridging the gap in patient profiling. PLoS ONE 2013; 8(1): e54728.

A retrospective cohort study of cancer incidence among patients treated with radiosynoviorthesis - Infante-Rivard C, Rivard G-É, Derome F, Cusson A, Winikoff R, Chartrand R, Guay JP. A retrospective cohort study of cancer incidence among patients treated with radiosynoviorthesis. Haemophilia 2012; 18(5): 805-809.

The effect of cooling on coagulation and haemostasis: should "Ice" be part of treatment of acute haemarthrosis in haemophilia? - Forsyth AL, Zourikian N, Valentino LA, Rivard G-É. The effect of cooling on coagulation and haemostasis: should "Ice" be part of treatment of acute haemarthrosis in haemophilia?. Haemophilia 2012; 18(6): 843-850.

Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond - Forsyth AL, Rivard G-É, Valentino LA, Zourikian N, Hoffman M, Monahan PE, Van Meegeren ME, Forriol F. Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond. Haemophilia 2012; 18(suppl 4): 112-119.

Low prevalence of inhibitor antibodies in the Canadian haemophilia population - Webert KE, Rivard G-É, Teitel J, Carcao M, Lillicrap D, St-Louis J, Walker BR. Low prevalence of inhibitor antibodies in the Canadian haemophilia population. Haemophilia 2012; 18(3): e254-259.

Simultaneous measurement of adenosine triphosphate release and aggregation potentiates human platelet aggregation responses for some subjects, including persons with Quebec platelet disorder - Hayward C, Moffat KA, Castilloux J, Liu Y, Seecharan J, Tasneem S, Carlino S, Cormier A, Rivard G-É. Simultaneous measurement of adenosine triphosphate release and aggregation potentiates human platelet aggregation responses for some subjects, including persons with Quebec platelet disorder. Thromb Haemost 2012; 107(4): 726-734.

Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A - Foley JH, Nesheim ME, Rivard G-É, Brummel Ziedins K. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A. Haemophilia 2012; 18(3): e316-322.

The influence of prophylactic factor VIII in severe haemophilia A - Gissel M, Whelihan MF, Ferris LA, Mann K, Rivard G-É, Brummel Ziedins K. The influence of prophylactic factor VIII in severe haemophilia A. Haemophilia 2012; 18(2): 193-199.

An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group - Lundin B, Manco-Johnson ML, Ignas DM, Moineddin R, Blanchette VB, Dunn A, Gibikote SV, Keshava SN, Ljung R, Manco-Johnson MJ, Miller S, Rivard G-É, Doria A, International Prophylaxis Study Group. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia 2012; 18(6): 962-970.

Why should we care about quality of life in persons with haemophilia? - Aledort LM, Bullinger M, Von Mackensen S, Wasserman J, Young NL, Globe D, Rivard G-É, Healthrelated Quality Of Life Expert Working Group Of The International Prophylaxis Study Group. Why should we care about quality of life in persons with haemophilia?. Haemophilia 2012; 18(3): e154-e157.

The principal results of the International Immune Tolerance Study: a randomized dose comparison - Hay C, Dimichele D, Rivard G-É, International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119(6): 1335-1344.

Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada - Kraft J, Blanchette V, Babyn P, Feldman BM, Cloutier S, Israels S, Pai M, Rivard G-É, Gomer S, McLimont M, Moineddin R, Doria A. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost 2012; 10(12): 2494-2502.

Quebec platelet disorder - Hayward C, Rivard G-É. Quebec platelet disorder. Exp Rev Hematol 2011; 4(2): 137-141.

Is testing for aspirin response worthwhile in high-risk pregnancy? - Rey E, Rivard G-É. Is testing for aspirin response worthwhile in high-risk pregnancy?. Eur J Obstet Gynecol Reprod Biol 2011; 157(1): 38-42.

Intravenous injection of autologous amniotic fluid induces transient thrombocytopenia in a gravid rabbit model of amniotic fluid embolism - Rannou B, Rivard G-É, Gains MJ, Bédard C. Intravenous injection of autologous amniotic fluid induces transient thrombocytopenia in a gravid rabbit model of amniotic fluid embolism. Vet Clin Pathol 2011; 40(4): 524-529.

Standardization of thromboelastography: a report from the TEG-ROTEM working group - Chitlur M, Sorensen B, Rivard G-É, Young G, Ingerslev J, Othman M, Nugent D, Kenet G, Escolar M, Lusher J. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia 2011; 17(3): 532-537.

Platelet disorders in children: A diagnostic approach - Israels S, Kahr W, Blanchette VS, Luban N, Rivard G-É, Rand ML. Platelet disorders in children: A diagnostic approach. Pediatr Blood Cancer 2011; 56(6): 975-983.

Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study - Hang M, Blanchette VS, Pullenayegum E, McLimont M, Feldman BM, Rivard G-É, Canadian Hemophilia Primary Prophylaxis Study Group. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2011; 9(5): 1067-1069.

Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment - Blavignac J, Bunimov N, Rivard G-É, Hayward C. Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment. Semin Thromb Hemost 2011; 37(6): 713-720.

Validation of a new pediatric joint scoring system from the international hemophilia prophylaxis study group: Validity of the hemophilia joint health score (HJHS) - Feldman BM, Funk SM, Bergstrom BM, Zourikian N, Hillard P, van der Net J, Engelbert R, Petrini P, Van den Berg HM, Manco-Johnson MJ, Rivard G-É, Abad A, Blanchette VS. Validation of a new pediatric joint scoring system from the international hemophilia prophylaxis study group: Validity of the hemophilia joint health score (HJHS). Arthritis Care Res (Hoboken) 2011; 63(2): 223-330.

Immune tolerance induction for a patient with factor IX inhibitors - a case report - Nagel K, Lauderbach L, Rivard G-É, Jardine L, Chan AK, Pai MK. Immune tolerance induction for a patient with factor IX inhibitors - a case report. Haemophilia 2011; 17(2): 315.

3-deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase - Raynal NJ, Momparler LF, Rivard G-É, Momparler RL. 3-deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase. Leukemia Res 2011; 35(1): 110-118.

3-deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase - Raynal NJ-M, Momparler LF, Rivard G-É, Momparler RL. 3-deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase. Leukemia Res 2011; 35(1): 110-118.

Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1 - Brummel Ziedins K, Whelihan MF, Rivard G-É, Butenas S. Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1. J Thromb Haemost 2011; 9(11): 2262-2267.

Cortactin activation by FVIIa/tissue factor and PAR2 promotes endothelial cell migration - Zhu T, Mancini J, Sapieha P, Yang C, Joyal JS, Honoré JC, Leduc M, Zaniolo K, Hardy P, Shao Z, Fan L, Hou X, Rivard G-É, Chemtob S. Cortactin activation by FVIIa/tissue factor and PAR2 promotes endothelial cell migration. Am J Physiol Regul Integr Comp Physiol 2011; 300(3): R577-585.

Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene - Paterson A, Rommens J, Bharaj B, Blavignac J, Wong I, Diamandis M, Waye JS, Rivard G-É, Hayward C. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood 2010; 115(6): 1264-1266.

C3, C5, and factor B bind to chitosan without complement activation - Marchand C, Bachand J, Périnêt J, Baraghis E, Lamarre M, Rivard G-É, De Crescenzo G, Hoemann CD. C3, C5, and factor B bind to chitosan without complement activation. J Biomed Mater Res A 2010; 93(4): 1429-1441.

Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells - Provençal M, Berger-Thibault N, Labbe D, Veitch R, Boivin D, Rivard G-É, Béliveau R. Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells. J Neurooncol 2010; 97(3): 365-372.

Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage? - Brunel-Guitton C, Rivard G-É, Galipeau J, Alos N, Miron MC, Therrien R, Mitchell GA, Lapierre J-G, Lambert MA. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?. Mol Genet Metab 2009; 96(2): 73-76.

Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation - Veljkovic D, Rivard G-É, Diamandis M, Blavignac J, Cramer-Bordé EM, Hayward C. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood 2009; 113(7): 1535-1542.

Solidification mechanisms of chitosan-glycerol phosphate/blood implant for articular cartilage repair. - Marchand C, Rivard G-É, Sun J, Hoemann CD. Solidification mechanisms of chitosan-glycerol phosphate/blood implant for articular cartilage repair.. Osteoarthr Cartilage 2009; 17(7): 953-960.

Low-dose ASA response using the PFA-100 in women with high-risk pregnancy - Caron N, Rivard G-É, Michon N, Morin F, Pilon D, Moutquin JM, Rey E. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. J Obstet Gynaecol Can 2009; 31(11): 1022-1027.

Quantitation of anti-factor VIII antibodies in human plasma - Krudysz-Amblo J, Parhami-Seren B, Butenas S, Brummel Ziedins K, Gomperts E, Rivard G-É, Mann K. Quantitation of anti-factor VIII antibodies in human plasma. Blood 2009; 113(11): 2587-2594.

Postpartum acquired haemophilia: a single centre experience with rituximab - Dedeken L, St-Louis J, Demers C, Meilleur C, Rivard G-É. Postpartum acquired haemophilia: a single centre experience with rituximab. Haemophilia 2009; 15(5) : 1166-1168.

Non-neutralizing anti-FVIII antibodies: different binding specificity to different recombinant FVIII concentrates - Vincent AM, Lillicrap D, Boulanger A, Meilleur C, Amesse C, St-Louis J, Rivard G-É. Non-neutralizing anti-FVIII antibodies: different binding specificity to different recombinant FVIII concentrates. Haemophilia 2009; 15(1): 374-376.

Thrombin generation and bleeding in haemophilia A - Brummel Ziedins K, Whelihan MF, Gissel M, Mann K, Rivard G-É. Thrombin generation and bleeding in haemophilia A. Haemophilia 2009; 15(5): 1118-1125.

Empirical and theoretical phenotypic discrimination - Brummel Ziedins K, Orfeo T, Rosendaal FR, Undas A, Rivard G-É, Butenas S, Mann K. Empirical and theoretical phenotypic discrimination. Haemophilia 2009; 7 (suppl 1): 181-186.

Measuring patient-reported outcomes in haemophilia clinical research - Globe D, Young NL, Von Mackensen S, Bullinger M, Wasserman J, Rivard G-É, Healthrelated Quality Of Life Expert Working Group Of The International Prophylaxis Study Group. Measuring patient-reported outcomes in haemophilia clinical research. Haemophilia 2009; 15(4): 843-852.

c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration. - Provençal M, Labbe D, Veitch R, Bovin D, Rivard G-É, Sartelet H, Robitaille Y, Gingras D, Béliveau R. c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration.. Carcinogenesis 2009; 30(7): 1089-1096.

Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care - Teitel JM, Carcao M, Lillicrap D, Mulder K, Rivard G-É, St-Louis J, Smith F, Walker I, Zourikian N. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009; 15(1): 227-239.

Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes - Diamandis M, Paterson A, Rommens J, Veljkovic D, Blavignac J, Bulman DE, Waye JS, Derome F, Rivard G-É, Hayward C. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. Blood 2009; 113(7): 1543-1546.

Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease - Rivard G-É, Aledort LM, Alphanate Surgical Investigators. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia 2008; 14(2): 271-275.

Reliability and construct validity of the compatible MRI scoring system for evaluation of elbows in haemophilic children - Doria A, Lundin B, Miller S, Kilcoyne RF, Dunn A, Thomas S, Rivard G-É, Moineddin R, Babyn P, Expert Imaging Working Group of The International Prophylaxis Study Group. Reliability and construct validity of the compatible MRI scoring system for evaluation of elbows in haemophilic children. Haemophilia 2008; 14(2): 303-314.

Evaluation of urokinase plasminogen activator in urine from individuals with Quebec platelet disorder - Diamandis M, Veljkovic D, Derome F, Rivard G-É, Hayward C. Evaluation of urokinase plasminogen activator in urine from individuals with Quebec platelet disorder. Blood Coagul Fibrin 2008; 19(5): 463-464.

Quebec platelet disorder: features, pathogenesis and treatment - Diamandis M, Veljkovic D, Rivard G-É. Quebec platelet disorder: features, pathogenesis and treatment. Blood Coagul Fibrin 2008; 19(2): 109-119.

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema - Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, Ritchie B, Farkas H, Varga L, Zingale L, Binkley K, Wagner É, Adomaitis P, Brosz K, Burnham J, Warrington R, Kalicinsky C, Mace S, McCusker C, Schellenberg R, Celeste L, Hébert J, Valentine K, Poon MC, Serushago B, Neurath G, Yang W, Lacuesta G, Issekutz A, Hamed A, Kamra P, Dean J, Kanani A, Stark D, Rivard G-É, Leith E, Tsai E, Waserman S, Keith PK, Page D, Marchesin S, Longhurst HJ, Kreuz W, Risicke E, Martinez-Saguer I, Aygoren-Pursun E, Harmat G, Füst G, Li H, Bouillet L, Caballero T, Moldovan D, Späth PJ, Smith-Foltz S, Nagy I, Nielsen EW, Bucher C, Nordenfelt P, Xiang ZY. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100(1 suppl 2): S30-40.

Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins - Provençal M, Michaud M, Beaulieu E, Ratel D, Rivard G-É, Gringras D, Béliveau R. Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins. Thromb Haemost 2008; 99(3): 576-585.

Periostin: a member of a novel family of vitamin k-dependent proteins is expressed by mesenchymal stromal cells - Coutu DL, Wu H, Monette A, Rivard G-É, Blostein M, Galipeau J. Periostin: a member of a novel family of vitamin k-dependent proteins is expressed by mesenchymal stromal cells. J Biol Chem 2008; 283(26): 17991-18001.

The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework - Moltzan C, Anderson D, Callum J, Fremes S, Hume HA, Mazer CD, Poon MC, Rivard G-É, Rizoli S, Robinson S. The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework. Transfus Med 2008; 18(2): 112-120.

A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose - Rubinger M, Lillicrap D, Rivard G-É, Teitel J, Carcao M, Hensman C, Walker I, Association of Hemophilia Clinic Directors of Canada. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14(2): 281-286.

Glanzmann thrombasthenia in an Oldenbourg filly - Maciera S, Rivard G-É, Champagne J, Lavoie JP, Bédard C. Glanzmann thrombasthenia in an Oldenbourg filly. Vet Clin Pathol 2007; 36(2): 204-208.

Chitosan–glycerol phosphate/blood implants elicit hyaline cartilage repair integrated with porous subchondral bone in microdrilled rabbit defects - Hoemann CD, Sun J, McKee MD, Chevrier A, Rossomacha E, Rivard G-É, Hurtig M, Buschmann M. Chitosan–glycerol phosphate/blood implants elicit hyaline cartilage repair integrated with porous subchondral bone in microdrilled rabbit defects. Osteoarthr Cartilage 2007; 15(1): 78-89.

VEGF increases the fibrinolytic activity of endothelial cells withing fibrin matrices: Involvement of VEGFR-2, tissue type plasminogen activator and matrix metalloproteinases - Ratel D, Mihoubi S, Beaulieu E, Durocher Y, Rivard G-É, Gingras D, Béliveau R. VEGF increases the fibrinolytic activity of endothelial cells withing fibrin matrices: Involvement of VEGFR-2, tissue type plasminogen activator and matrix metalloproteinases. Thromb Res 2007; 121(2): 203-212.

Generation of kinins during preparation and storage of whole blood-derived platelet concentrates - Moreau M, Thibault L, Désormeaux A, Chagnon M, Lemieux R, Robillard P, Marceau F, Colman RW, Lepage Y, Rivard G-É, Adada B. Generation of kinins during preparation and storage of whole blood-derived platelet concentrates. Transfusion 2007; 47(3): 410-420.

International workshop on immune tolerance induction: consensus recommendations - Dimichele D, Hoots WK, Pipe SW, Rivard G-É, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 12(suppl. 1): 1-22.

The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study - James PD, Notley CRP, Hegadorn CA, Geggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brian L, Othman M, Rivard G-É, Rapson D, Hough C, Lillicrap D. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007; 109(1): 145-154.

Canadian multi-institutional survey of immune tolerance therapy (ITT) -- experience with the use of recombinant factor VIII for ITT - Barnes C, Rivard G-É, Poon MC, Teitel J, Pai M, Kern M, Blanchette VS, Carcao M. Canadian multi-institutional survey of immune tolerance therapy (ITT) -- experience with the use of recombinant factor VIII for ITT. Haemophilia 2006; 12(1): 1-6.

Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWB study - James PD, Lillicrap D, Rivard G-É, and the Association of Hemophilia Clinic Director of Canada. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWB study. J Thromb Haemost 2006; 4: 783-792.

Systemic capillary leak syndrome presenting as recurrent shock - Karatzios C, Gauvin F, Egerszegi PE, Tapiero B, Buteau C, Rivard G-É, Ovetchkine P. Systemic capillary leak syndrome presenting as recurrent shock. Pediatr Crit Care Med 2006; 7(4): 377-379.

Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study - Feldman BM, Pai M, Rivard G-É, Israel S, Poon MC, Demers C, Robinson S, Luke KH, Wu JK, Gill K, Lillicrap D, Babyn P, McLimont MJ, Blanchette VS, and the Association of Hemophilia Clinic Director of Canada. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4(6): 1228-1236.

Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis - Diamandis M, Adam F, Kahr W, Wang P, Chorneyko KA, Arsenault AL, Rivard G-É, Hayward C. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. J Thromb Haemost 2006; 4(5): 1086-1094.

Reliability and construct validity of the compatible MRI scoring system for evaluation of haemophilic knees and ankles of haemophilic children. Expert MRI working group of the international prophylaxis study group - Doria A, Babyn P, Lundin B, Kilcoyne RF, Miller S, Rivard G-É, Moineddin R, Pettersson H. Reliability and construct validity of the compatible MRI scoring system for evaluation of haemophilic knees and ankles of haemophilic children. Expert MRI working group of the international prophylaxis study group. Haemophilia 2006; 12(5): 503-513.

Stimulation of tPA-dependent provisional extracellular fibrin matrix degradation by human recombinant soluble melanotransferrin - Bertrand Y, Demeule M, Rivard G-É, Béliveau R. Stimulation of tPA-dependent provisional extracellular fibrin matrix degradation by human recombinant soluble melanotransferrin. Biochim Biophys Acta - Mol Cell Res 2006; 1763(10): 1024-1030.

Mortality rates causes of death among all HIV-positive individual with hemophilia on Canada over 21 years of follow-up - Arnold DL, Julien JA, Walker I, Winikoff R, Rivard G-É, and the Association of Hemophilia Clinic Director of Canada. Mortality rates causes of death among all HIV-positive individual with hemophilia on Canada over 21 years of follow-up. Blood 2006; 108(2): 460-464.

Proangiogenic effects of protease-activated receptor 2 are tumor necrosis factor-alpha and consecutively Tie2 dependent - Zhu T, Sennlaub F, Beauchamp M, Fan L, Joyal JS, Checchin D, Nim S, Lachapelle P, Sirinyan M, Hou X, Bossolasco M, Rivard G-É, Heveker N, Chemtob S. Proangiogenic effects of protease-activated receptor 2 are tumor necrosis factor-alpha and consecutively Tie2 dependent. Arterioscler Thromb Vasc Biol 2006; 26(4): 744-750.

Cardiac tamponade in a patient with moderate hemophilia A and factor VIII inhibitors - Ghosh N, Teefy PJ, Lauderbach L, Rivard G-É. Cardiac tamponade in a patient with moderate hemophilia A and factor VIII inhibitors. Can J Cardiol 2006; 22(1): 73-75.

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience - Carcao M, St-Louis J, Poon MC, Grunebaum E, Lacroix S, Stain AM, Blanchette VS, Rivard G-É. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006; 12(1): 7-18.

Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age? - Rivard G-É, Lillicrap D, Poon MC, Demers C, Lepine M, St-Louis J, Warner M. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?. Haemophilia 2005; 11(4): 335-339.

Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography - Rivard G-É, Brummel Ziedins K, Mann K, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3(9): 2039-2043.

Thrombophilic polymorphisms and intrauterine growth restriction - Infante-Rivard C, Rivard G-É, Guiguet M, Gauthier R. Thrombophilic polymorphisms and intrauterine growth restriction. Epidemiology 2005; 16(3): 281-287.

Studies on rabbit natural and recombinant tissue factors: intracellular retention and regulation of surface expression in cultured cells - Fortin J, Rivard G-É, Adam A, Marceau F. Studies on rabbit natural and recombinant tissue factors: intracellular retention and regulation of surface expression in cultured cells. Am J Physiol Heart Circ Physiol 2005; 288(5): H2192-2202.

Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: Expert MRI Working Group of the International Prophylaxis Study Group Haemophilia - Doria A, Lundin B, Kilcoyne RF, Babyn P, Miller S, Nuss R, Rivard G-É, Stephens D, Pettersson H. Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: Expert MRI Working Group of the International Prophylaxis Study Group Haemophilia. Haemophilia 2005; 11: 245-253.

Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy - Lundin B, Babyn P, Doria A, Kilcoyne RF, Ljung R, Ljung R, Nuss R, Rivard G-É, Pettersson H. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia 2005; 11(2): 109-115.

Tissue factor enhances protease activated receptor-2-mediated factor VIIa cell proliferative properties - Fan L, Yotov WV, Zhu T, Esmailzadeh L, Joyal JS, Sennlaub F, Heveker N, Chemtob S, Rivard G-É. Tissue factor enhances protease activated receptor-2-mediated factor VIIa cell proliferative properties. J Thromb Haemost 2005; 3(5): 1056-1063.

The syndrome of amniotic fluid embolization: A potential contribution of bradykinin - Robillard J, Gauvin F, Molinaro G, Leduc L, Adam A, Rivard G-É. The syndrome of amniotic fluid embolization: A potential contribution of bradykinin. Am J Obstet Gynecol 2005; 193(4): 1508-1512.

Aminoglycoside suppression of nonsense mutations in severe hemophilia - James PD, Raut S, Rivard G-É, Poon MC, Warner M, McKenna S, Leggo J, Lillicrap D. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 2005; 106(9): 3043-3048.

Can laboratory tests differenciate between coagulation inhibitors? - Rivard G-É. Can laboratory tests differenciate between coagulation inhibitors?. Haemophilia 2004; 10: 1-3.

Inhibitors in haemophilia: clinical aspect - Dimichele D, Rivard G-É, Hay C, Antunes S. Inhibitors in haemophilia: clinical aspect. Haemophilia 2004; 10(suppl. 4): 140-145.

Factor VIIa replacement therapy in factor VII deficiency - Brummel Ziedins K, Rivard G-É, Pouliot RL, Butenas S, Gissel M, Parhami-Seren B, Mann K. Factor VIIa replacement therapy in factor VII deficiency. J Thromb Haemost 2004; 2: 1735-1744.

Unexpected relationship between plasma homocysteine and intra uterine growth restriction: response - Infante-Rivard C, Rivard G-É. Unexpected relationship between plasma homocysteine and intra uterine growth restriction: response. Clin Chem 2004; 50: 784-785.

A survey of factor prophylaxis in the Canadian Haemophilia A population - Blanchette P, Rivard G-É, Israel S, Robinson S, Ali K, Walker I, Stain AM, Blanchette V. A survey of factor prophylaxis in the Canadian Haemophilia A population. Haemophilia 2004; 10: 679-683.

Gaucher disease: variability in phenotype among sibblings - Amato D, Stachiw T, Clarke JTR, Rivard G-É. Gaucher disease: variability in phenotype among sibblings. J Inherit Metab Dis 2004; 27: 659-669.

Elective orthopaedic surgery for hemophilia patients with inhibitors: new opportunities - Rodriguez-Merchan EC, Wiedel JD, Wallmy T, Caviglia H, Hvid J, Bernterp E, Rivard G-É, Goddard NJ, Querd F. Elective orthopaedic surgery for hemophilia patients with inhibitors: new opportunities. Semin Hematol 2004; 41(1 suppl. 1): 109-116.

Consensus recommendations for use of central venous access devices in haemophilia - Ewenstein B, Valentino LA, Journeycake JM, Tarantino MD, Shapiro A, Blanchette VS, Hoots WK, Buchanan GR, Manco-Johnson MJ, Rivard G-É, Miller K, Geraghty S, Maahs JA, Stuart R, Dunham T, Navickis RJ. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004; 10(5): 629-648.

Bleeding risks associated with inheritance of the Quebec platelet disorder - McKay H, Derome F, Haq MA, Whittaker S, Arnold E, Adam F, Heddle NM, Rivard G-É, Hayward C. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104(1): 159-165.

Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema - Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, Zingale L, Varga L, Martinez-Saguer I, Aygoren-Pursun E, Binkley K, Zuraw B, Davis A, Hébert J, Ritchie B, Burnham J, Castaldo A, Menendez A, Nagy I, Harmat G, Bucher C, Lacuesta G, Issekutz A, Warrington R, Yang W, Dean J, Kanani A, Stark D, McCusker C, Wagner E, Rivard G-É, Leith E, Tsai E, Macsween M, Lyanga J, Serushago B, Leznoff A, Waserman S, De Serres J. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol 2004; 114(3): 629-637.

Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of ten consecutive cases from a single institution - Rivard G-É, St-Louis J, Lacroix S, Champagne M, Rock G. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of ten consecutive cases from a single institution. Haemophilia 2003; 9(6): 711-716.

Status and challenges of chemical and radiosynovectomy - Rivard G-É. Status and challenges of chemical and radiosynovectomy. Biom Prog 2003; 15: 4-6.

Unexpected relationship between plasma homocysteine and intrauterine growth restriction - Infante-Rivard C, Rivard G-É, Gauthier R, Théorêt Y. Unexpected relationship between plasma homocysteine and intrauterine growth restriction. Clin Chem 2003; 49(9): 1476-1482.

Intracellular activation of the fibrinolytic cascade in Quebec Platelet Disorder - Sheth PM, Kahr WHA, Anwar Hog M, Veljkovic D, Rivard G-É, Hayward C. Intracellular activation of the fibrinolytic cascade in Quebec Platelet Disorder. Thromb Haemost 2003; 90: 293-298.

Mannan-binding lectin in children with Escherichia coli O 157:H7 haemorrhagic colitis and haemolitic uraemia syndrome - Proulx F, Wagner É, Toledano B, Decaluwé H, Seidman EG, Rivard G-É. Mannan-binding lectin in children with Escherichia coli O 157:H7 haemorrhagic colitis and haemolitic uraemia syndrome. Clin Exp Immunol 2003; 133(3): 360-363.

Small babies receive the cardiovascular protective apoliprotein epsilon 2 allele less frequently than expected - Infante-Rivard C, Levy E, Rivard G-É, Guinguet M, Feoli-Fonseca J-C. Small babies receive the cardiovascular protective apoliprotein epsilon 2 allele less frequently than expected. J Med Genet 2003; 40(8): 626-629.

Oxidative tyrosylation of high density lipoproteins impairs cholesterol efflux from mouse J774 macrophages: role of scavenger receptors, classes A and B - Suc I, Brunet S, Mitchell GA, Rivard G-É, Levy E. Oxidative tyrosylation of high density lipoproteins impairs cholesterol efflux from mouse J774 macrophages: role of scavenger receptors, classes A and B. J Cell Sci 2003; 116(Pt 1): 89-99.

An evaluation of the stability of factor VIII inhibitors in plasma and plasma dried on filter paper discs stored at room temperature - Winikoff R, Boulanger A, St-Louis J, Lacroix S, Rivard G-É. An evaluation of the stability of factor VIII inhibitors in plasma and plasma dried on filter paper discs stored at room temperature. Haemophilia 2003; 9: 57-59.

Optimisation of storage conditions for diluted working solutions of porcine factor VIII and performance of the Bethesda assay for the determination of antiporcine FVIII inhibitor titres - Winikoff R, Boulanger A, St-Louis J, Lacroix S, Rivard G-É. Optimisation of storage conditions for diluted working solutions of porcine factor VIII and performance of the Bethesda assay for the determination of antiporcine FVIII inhibitor titres. Haemophilia 2003; 9: 104-109.

Founder von Willebrand factor haptotype associated with type 1 von Willebrand disease - O'Brien LA, James PD, Othman M, Berner E, Cameron C, Notley CRP, Hegadorn CA, Sutherland JJ, Hough C, Rivard G-É, O'Shawnessey D, Lillicrap D. Founder von Willebrand factor haptotype associated with type 1 von Willebrand disease. Blood 2003; 102: 549-557.

Elective orthopaedic surgery for inhibitor patients - Rodriguez-Merchan EC, Wiedel JD, Wallmy T, Hvid J, Beantorp S, Rivard G-É, Goddard NJ, Querol F, Cariglia H. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003; 9(5): 625-631.

A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres - Blanchette VS, McCready M, Achoner C, Abdolell M, Rivard G-É, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9(suppl. 1): 19-26.

Use of protein-A column and porcine factor VIII - Rivard G-É. Use of protein-A column and porcine factor VIII. Haemophilia 2002; 8(2): 20-23.

Stability of total plasma homocysteine in perinatology - Théorêt Y, Rivard G-É, Infante-Rivard C, Yotov WV. Stability of total plasma homocysteine in perinatology. Clin Chimica Acta 2002; 319(1): 63-66.

Absence of association of thrombophilia polymorphisms with intrauterine growth restriction - Infante-Rivard C, Rivard G-É, Yotov WV, Génin E, Guiguet M, Weinberg C, Gauthier R, Feoli-Fonseca J-C. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002; 347(1): 19-25.

Perinatal reference ranges for plasma homocysteine and factors influencing levels - Infante-Rivard C, Rivard G-É, Yotov WV, Théorêt Y. Perinatal reference ranges for plasma homocysteine and factors influencing levels. Clin Chem 2002; 48(7): 1100-1102.

Thrombophilia polymorphisms and intrauterine growth restriction (lettre) - Infante-Rivard C, Rivard G-É, Gauthier R. Thrombophilia polymorphisms and intrauterine growth restriction (lettre). N Engl J Med 2002; 347: 1530-1531.

The recombinant factor IX investigator group's response to Dr Hoose (lettre) - Roth DA, Rivard G-É, et al. The recombinant factor IX investigator group's response to Dr Hoose (lettre). Blood 2002; 100: 4243.

Chemical synovectomy in haemophilia: status and challenges - Rivard G-É. Chemical synovectomy in haemophilia: status and challenges. Haemophilia 2001; 7(2): 16-19.

Optimal treatment regiments for patients with bleeding disorders - Brown A, Aledort LM, Lee CA, Rivard G-É, et al. Optimal treatment regiments for patients with bleeding disorders. Haemophilia 2001; 7: 313-320.

Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator - Kahr WHA, Zheng S, Sheth PM, Pai M, Cowie A, Bouchard M, Podor TJ, Rivard G-É, Hayward C. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001; 98(2): 257-265.

Prophylaxis and treatment of thromboembolic diseases in pregnancy with dalteparin - Rey E, Rivard G-É. Prophylaxis and treatment of thromboembolic diseases in pregnancy with dalteparin. Int J Gynecol Obstet 2000; 71(1): 19-24.

Suggestions for the management of factor VIII inhibitors - Rubinger M, Rivard G-É, Teitel J, Walker I. Suggestions for the management of factor VIII inhibitors. Haemophilia 2000; 6: 52-59.

Late clinical, plain X-ray and magnetic resonance imagery findings in haemophilic joints treated with radiosynoviorthesis - Nuss R, Kilcoyne RF, Rivard G-É, Murphy J. Late clinical, plain X-ray and magnetic resonance imagery findings in haemophilic joints treated with radiosynoviorthesis. Haemophilia 2000; 6: 658-663.

Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma - Yotov WV, Hamel H, Rivard G-É, Champagne M, Russo P, Leclerc JM, Bernstein M, Levy E. Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma. Gene Chromosomes Cancer 1999; 26: 62-69.

Surveillance for factor HIV inhibitor development in the Canadian Hemophilia A. A population following the wide spread introduction of recombinant factor A replacement therapy - Giles AR, Rivard G-É, Teitel J, Walker I. Surveillance for factor HIV inhibitor development in the Canadian Hemophilia A. A population following the wide spread introduction of recombinant factor A replacement therapy. Transfus Sci 1998; 19: 139-148.

A detailed comparaison of the performance of the standard versus Nijmegen modification of the Bethesda Assay in the haemophilia: A population of Canada - Giles AR, Verbruggen B, Rivard G-É, Teitel J, Walker I. A detailed comparaison of the performance of the standard versus Nijmegen modification of the Bethesda Assay in the haemophilia: A population of Canada. Thromb Haemost 1998; 79: 872-875.

Causes of death in Canadians with Hemophilia 1980-1995 - Walker IR, and the Association of Hemophilia Clinic Director of Canada, David M, Rivard G-É. Causes of death in Canadians with Hemophilia 1980-1995. Haemophilia 1998; 4: 714-720.

Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate - Teitel JM, and the Association of Hemophilia Clinic Director of Canada, Rivard G-É. Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. Haemophilia 1998; 4: 731-738.

Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the a-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to a-granule - Hayward C, Cramer E, Kane W, Zheng S, Bouchard M, Masse JM, Rivard G-É. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the a-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to a-granule. Blood 1997; 89: 1243-1253.

Fibrinogen degradation products in patients with the Quebec platelet disorder - Hayward C, Welch B, Bouchard M, Zheng S, Rivard G-É. Fibrinogen degradation products in patients with the Quebec platelet disorder. Brit J Haematol 1997; 97: 997-1053.

An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombocytopenia, Von Willebrand factor and fibrinogen, and epinephrin aggregation defect - Hayward C, Rivard G-É, Kane W, Drouin J, Zheng S, Moore JC, Hugees M, Kelton J. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombocytopenia, Von Willebrand factor and fibrinogen, and epinephrin aggregation defect. Blood 1996; 87: 4967-4978.

Factor V Quebec revisited - Janeway CM, Rivard G-É, Tracy PB, Mann K. Factor V Quebec revisited. Blood 1996; 87: 3571-3578.

Mediastinal bleeding after cardiopulmonary bypass in pediatric patients - Guay J, Rivard G-É. Mediastinal bleeding after cardiopulmonary bypass in pediatric patients. Ann Thorac Surg 1996; 62: 1955-1960.

Factor IX inhibitors and anaphylaxis in hemophilia B - Warrier I, Ewenstein B, Koerper M, Shapiro A, Key N, Di Michele D, Miller R, Pasi J, Rivard G-É, Sommer S, Katz J, Lusher JM. Factor IX inhibitors and anaphylaxis in hemophilia B. Haemophilia 1996; 2: 259-260.

Factor IX inhibitors and anaphylaxis in hemophilia - Warrier I, Ewenstein B, Koerper M, Shapiro A, Key N, Di Michele D, Miller R, Pasi J, Rivard G-É, Sommer S, Katz J, Bergman F, Lying R, Petrini P, Lusher J. Factor IX inhibitors and anaphylaxis in hemophilia. Pediatr Hematol Oncol 1996; 19: 1-5.

À propos de cette page

Créée le 22 juillet 2014
Signaler ou faire une remarque

Chaque dollar compte !

Merci de votre générosité.

Ce sont les donateurs comme vous qui nous permettent d’accélérer la recherche, de guérir, à chaque année, plus d’enfants et continuer d’offrir un des meilleurs niveaux de santé au monde.

Il est également possible de donner par la poste ou de donner par téléphone au numéro sans frais

1-888-235-DONS (3667)

Nous contacter

514 345-4931

Légal

© 2006-2014 Centre de recherche du CHU Sainte-Justine.
Tous droits réservés.
Avis légaux  Confidentialité  Sécurité

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine